OncoGenex Pharmaceuticals Inc.'s CFO and PFO was just granted 60,000 options and restricted shares


John Bencich, OncoGenex Pharmaceuticals Inc.'s CFO and PFO, just received 60,000 options and restricted shares from the company. The strike prices of the options received ranged from $0.00 to $3.17, and these expire on August 12, 2024. The restricted shares don't become available to Bencich until such time as they become vested. Bencich now has at least 40,000 options, and at least 2,000 restricted shares.

Some additional info was provided as follows:

This amended Form 4 is filed to correct (a) the exercise price, which was inadvertently reported as $3.30, (b) the transaction date, which was inadvertently reported as August 11, 2014 and (c) the expiration date, which was inadvertently reported as August 11, 2024. This amended Form 4 is filed to correct the exerc isable date. The options vest monthly over 48 months, commencing on September 12, 2014, which was inadvertently reported as September 11, 2014. Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock at settlement. This amended Form 4 is filed to correct the exercisable date. Twenty-five percent of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 12, 2014, which was inadvertently reported as August 11, 2014; and (ii) the first day thereafter during which the issuer's trading window is open. The RSUs expire 30 days from the date they vest.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever OncoGenex Pharmaceuticals Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

OncoGenex Pharmaceuticals Inc. just filed a General Statement of acquisition of beneficial ownership - Dec. 12, 2014

   Auto Refresh

Feedback